<DOC>
	<DOCNO>NCT01222013</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , molecular response event-free survival , use Imatinib conjunction chemotherapy BFM `` like '' Induction child ALL Ph+ .</brief_summary>
	<brief_title>Study Safety Efficacy Evaluation Imatinib Mesylate Children With Acute Lymphoblastic Leukemia ( ALL ) Philadelphia Chromosome-positive ( Ph+ )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Diagnose : therapynaïve ALL , except patient perform Induction ALL ( 33 day ) exactly protocol ; document Ph+ , confirm conventional cytogenetic ( 9 ; 22 ) ( q34 ; q11 ) FISH and/or gene BCRABL presence RTPCR FISH . 2 . Female patient childbearing age , pregnancy test ( blood βhCG ) perform treatment initiation . Effective contraception must use treatment . Pregnant woman wo n't include . 3 . Life expectation &gt; 8 week . 4 . Medications : antineoplastic treatmentnaïve , include corticotherapy , except patient perform Induction ALL ( 33 day ) exactly protocol . 5 . Signed ICF child legal responsible . 6 . Laboratory : renal function ( serum creatinine ≤ 1,5 x ULN and/or Clearance ≥70 ml/min/1,73m2 ) , hepatic function ( total bilirubin ≤ 1,5 x ULN , TGP/TGO &lt; 10 x ULN albumin &gt; 2 g/dl . 1 . Any inclusion criterion miss . 2 . Pregnant patient breastfeeding . 3 . Patient consider incapable follow purpose treatment . 4 . Subject infectious process , activity , grade IV .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>